APA (7th ed.) Citation

Yau, T., Kang, Y., Kim, T., El-Khoueiry, A. B., Santoro, A., Sangro, B., . . . Hsu, C. (2020). Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA oncology, 6(11), e204564. https://doi.org/10.1001/jamaoncol.2020.4564

Chicago Style (17th ed.) Citation

Yau, Thomas, et al. "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial." JAMA Oncology 6, no. 11 (2020): e204564. https://doi.org/10.1001/jamaoncol.2020.4564.

MLA (9th ed.) Citation

Yau, Thomas, et al. "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial." JAMA Oncology, vol. 6, no. 11, 2020, p. e204564, https://doi.org/10.1001/jamaoncol.2020.4564.